The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer
Abstract
Purpose: Preclinical studies suggest that treatment with a selective cyclo-oxygenase-2 (COX-2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with non–small-cell lung cancer (NSCLC) were preoperatively treated with celecoxib in combination with chemotherapy. End points were toxicity, response rates, and measurement of intratumoral levels of prostaglandin E 2(PGE 2). Methods: In this phase II trial, 29 patients with stages IB to IIIA NSCLC were treated with two preoperative cycles of paclitaxel and carboplatin, as well as daily celecoxib, followed by surgical resection. Levels of PGE 2 in the primary tumors and adjacent normal lung tissue were compared in 17 study patients versus 13 controls, who received preoperative paclitaxel/carboplatin without celecoxib. Results: All patients completed preoperative chemotherapy, and 26 completed preoperative celecoxib. The overall clinical response rate was 65% (48% with partial response; 17% with complete response). Grade 3 or 4 neutropenia was observed in 18 patients (62%). Twenty-eight patients were explored and underwent complete resection of their tumors. There were no complete pathologic responses, but seven patients (24%) had minimal residual microscopic disease. The addition of celecoxib to a regimen of paclitaxel and carboplatin abrogated the marked increase in levels of PGE 2 detected in primary tumors after treatment with paclitaxel and carboplatin alone. Conclusion: In comparison with historically reported response rates, these data suggest that the addition of a selective COX-2 inhibitor may enhance the response to preoperative paclitaxel and carboplatin in patients with NSCLC. Moreover, treatment with celecoxib 400 mg twice daily was sufficient to normalize the increase in PGE 2 levels found in NSCLC patients after treatment with paclitaxel and carboplatin. Confirmatory trials are planned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., & Seibert, K. (2000) · PubMed · Cited by 1,401
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
Rosell, R., Gomez-Codina, J., Camps, C., Maestre, J., Padille, J., Canto, A., Mate, J. L., Li, S., Roig, J., Olazabal, A., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401203300301 · Cited by 1,261
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & Dubois, R. N. (1998) · PubMed · Cited by 1,114
Kawamori, T., Rao, C. V., Seibert, K., & Reddy, B. S. (1998) · PubMed · Cited by 916
COX-2 is expressed in human pulmonary, colonic, and mammary tumors
Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner, B. M., Khan, K. N., Masferrer, J., & Koki, A. T. (2000) · Cancer · doi:10.1002/1097-0142(20001215)89:12<2637::aid-cncr17>3.0.co;2-b · Cited by 862
Self-citationExpression of cyclooxygenase-2 in human lung carcinoma.
Wolff, H. J., Saukkonen, K., Anttila, S. L., Karjalainen, A., Vainio, H., & Ristimaki, A. P. (1998) · PubMed · Cited by 717
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., & DuBois, R. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119400 · Cited by 712
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.
Chan, G. G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P., Edelstein, D. R., Soslow, R. A., Koki, A. T., Woerner, B. M., et al. (1999) · PubMed · Cited by 706
Self-citationCyclooxygenase-2 expression is up-regulated in human pancreatic cancer.
Tucker, O., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., et al. (1999) · PubMed · Cited by 692
Self-citationHost cyclooxygenase-2 modulates carcinoma growth
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., & DuBois, R. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9621 · Cited by 673
Mizuno, H., Sakamoto, C., Matsuda, K., Wada, K., Uchida, T., Noguchi, H., Akamatsu, T., & Kasuga, M. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024292 · Cited by 637
Depierre, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.247 · Cited by 626
Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., et al. (1996) · PubMed · Cited by 545
Self-citationChemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Harris, R. E., Alshafie, G. A., Abou‐Issa, H., & Seibert, K. (2000) · PubMed · Cited by 540
Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer
Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., & Subbaramaiah, K. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00488-0 · Cited by 508
Self-citationHuang, M., Stolina, M., Sharma, S. P., Mao, J. T., Zhu, L. X., Miller, P. W., Wollman, J. S., Herschman, H. R., & Dubinett, S. M. (1998) · PubMed · Cited by 492
Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. J., & Lubet, R. A. (2000) · PubMed · Cited by 478
Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.361 · Cited by 465
Leahy, K. M., Ornberg, R., Wang, Y., Zweifel, B. S., Koki, A. T., & Masferrer, J. L. (2002) · PubMed · Cited by 438
Fischer, S. M., Lo, H.-H., Gordon, G. B., Seibert, K., Kelloff, G., Lubet, R. A., & Conti, C. J. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199908)25:4<231::aid-mc1>3.0.co;2-f · Cited by 408
INHIBITION OF CYCLOOXYGENASE-2 SUPPRESSES ANGIOGENESIS AND THE GROWTH OF PROSTATE CANCER IN VIVO
LIU, X. H., KIRSCHENBAUM, A., YAO, S., LEE, R., HOLLAND, J. F., & LEVINE, A. C. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67321-1 · Cited by 363
Subversion of immune system by tumor cells and role of prostaglandins.
Plescia, O. J., Smith, A. H., & Grinwich, K. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1848 · Cited by 352
Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J. W., Sessoms, A. R., Dunson, D. B., Rogan, E. G., Morham, S. G., Smart, R. C., et al. (2002) · PubMed · Cited by 344
Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2
Subbaramaiah, K., Hart, J. C., Norton, L., & Dannenberg, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.14838 · Cited by 300
Self-citationNon-small Cell Lung Cancer Cyclooxygenase-2-dependent Invasion Is Mediated by CD44
Dohadwala, M., Luo, J., Zhu, L., Lin, Y., Dougherty, G. J., Sharma, S., Huang, M., Põld, M., Batra, R. K., & Dubinett, S. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100140200 · Cited by 236
Sawaoka, H., Kawano, S., Tsuji, S., Tsujii, M., Gunawan, E. S., Takei, Y., Nagano, K., & Hori, M. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.274.6.g1061 · Cited by 235
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach
Pisters, K. M. W., Ginsberg, R. J., Giroux, D. J., Putnam, J. B., Kris, M. G., Johnson, D. H., Roberts, J. R., Mault, J., Crowley, J. J., & Bunn, P. A. (2000) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(00)70120-6 · Cited by 235
Enhancement of Tumor Response to -Radiation by an Inhibitor of Cyclooxygenase-2 Enzyme
Milas, L., Kishi, K., Hunter, N. R., Mason, K. A., Masferrer, J. L., & Tofilon, P. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1501 · Cited by 225
Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398.
Rioux, N., & Castonguay, A. (1998) · PubMed · Cited by 204
Pyo, H., Choy, H., Amorino, G. P., Js, K., Cao, Q., Hercules, S. K., & DuBois, R. N. (2001) · PubMed · Cited by 201
Trifan, O. C., Durham, W. F., Salazar, V. S., Horton, J., Levine, B. D., Zweifel, B. S., Davis, T. W., & Masferrer, J. L. (2002) · PubMed · Cited by 195
Alshafie, G. A., Abou-Issa, H. M., Seibert, K., & Harris, R. E. (2000) · Oncology Reports · doi:10.3892/or.7.6.1377 · Cited by 161
Kambayashi, T., Alexander, H. R., Fong, M., & Strassmann, G. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.7.3383 · Cited by 130
Shiotani, H., Denda, A., Yamamoto, K., Kitayama, W., Endoh, T., Sasaki, Y., Tsutsumi, N., Sugimura, M., & Konishi, Y. (2001) · PubMed · Cited by 112
Tomozawa, S., Nagawa, H., Tsuno, N. H., Hatano, K., Osada, T., Kitayama, J., Sunami, E., Nita, M. E., Ishihara, S., Yano, H., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6694262 · Cited by 112
Hida, T., Kozaki, K., Ito, H. M., Miyaishi, O., Tatematsu, Y., Suzuki, T., Matsuo, K., Sugiura, T., Ogawa, M., Takahashi, T., et al. (2002) · PubMed · Cited by 112
Nishimura, G., Yanoma, S., Mizuno, H., Kawakami, K., & Tsukuda, M. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00690.x · Cited by 101
Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil–induced myelotoxicity in mice
Lorenz, M., Slaughter, H. S., Wescott, D. M., Carter, S. I., Schnyder, B., Dinchuk, J. E., & Car, B. D. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00087-9 · Cited by 69
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis
Hsueh, C.-T., Chiu, C., Kelsen, D. P., & Schwartz, G. K. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051007 · Cited by 55
Cited by
Cyclooxygenase‐2 in cancer: A review
Hashemi Goradel, N., Najafi, M., Salehi, E., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27411 · Cited by 807
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Targeting cyclooxygenase-2 in human neoplasia
Dannenberg, A. J., & Subbaramaiah, K. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00310-6 · Cited by 446
Self-citationCyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
Dannenberg, A. J., Lippman, S. M., Mann, J. R., Subbaramaiah, K., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.112 · Cited by 404
Self-citationCyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj206 · Cited by 400
Metadata
- Authors
- Altorki, N. K., Keresztes, R. S., Port, J. L., Libby, D. M., Korst, R. J., Flieder, D. B., Ferrara, C. A., Yankelevitz, D. F., Subbaramaiah, K., Pasmantier, M. W., & Dannenberg, A. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-15
- Volume
- 21
- Issue
- 14
- Pages
- 2645-2650
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2117011972
- Cited by
- 275
- References
- 45
- FWCI
- 22.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.